UC Health hires first chief data and analytics officer

UC Health, an integrated academic health system based in Cincinnati, has named its first vice president and chief data and analytics officer. The creation of the executive position reflects the rising importance of data-driven strategies in healthcare organizations.

Michael Legg, MHA, has been appointed to the position, where he will collaborate with clinical and operational leadership to build up data-driven decision making. He will also work to establish a formal process for gathering, interpreting and sharing data, as well as establish a process for UC Health employees to access the right data at the right time.

“As our system’s first vice president and chief data and analytics officer, Mike will support UC Health’s commitment to driving innovation, leading the way our system collects, interprets and uses data and analytics to enhance the delivery of care and achieve operational excellence,” Evaline A. Alessandrini, MD, senior vice president & chief medical officer for UC Health, said in a statement.

Legg, who has more than 15 years of experience in leading change initiatives at large healthcare organizations, begins his role July 8. He formerly served as executive director or reporting and analytics for Yale-New Haven Health System, an organization with five hospitals and a multispecialty medical group with more than 8,200 medical staff and 25,000 employees.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.